NGR多肽修饰的脂质体及其抗肿瘤研究进展(6)
[31] Fabio P， Chiara B， Daniela D P， et al. Targeting liposomal chemotherapy via both tumor cell-speciic and tumor vasculature-specific ligands pdtentiates therapeutic efficacy[J]. Cancer Res， 2006(66)：10073.
[32] Luo L M， Huang Y， Zhao B X， et al. Anti-tumor and anti-angiogrnic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel[J]. Erials， 2013， 34(4)：1102.
Advance in studies on NGR peptide modified liposome and its
anti-tumor performance
WANG Yong1， CHEN Jun1*， LIN Ai-hua2*， FANG Yun3
(1.Pharmaceutical College of Nanjing University of Chinese Medicine， Nanjing 210046， China；
2.The Second Clinical Medicine College Affiliated to Guangzhou University of Chinese Medicine， Guangzhou 510120， China；
3.Department of Pharmacy， Gulou Hospital Affiliated to Nanjing University， Nanjing 210008， China)
[Abstract] Aspargine-glycine-arginine (NGR)-containing peptides are targeted peptides which can be integrated with CD13 receptors on tumor vascular endothelial cells. NGR peptides are connected to liposomes to obtain NGR peptide-modified liposomes. By intravenous injection of these liposomes， NGR peptides can be combined with CD13 receptors on tumor vascular endothelial cells， position liposomes in tumor tissues， and concentrate drug in liposomes in tumor， so as to enhance the antitumor effect. The article starts with NGR peptides， summarizes definition of NGR， NGR peptide-modified liposomes， strengths and weaknesses of NGR peptide-modified liposomes in antitumor and the latest study orientation of NGR peptide-modified liposomes， and looks into the future of studies on NGR peptide-modified liposomes.
[Key words] NGR peptide； NGR petide-modified liposomes； CD13 receptor； antitumor
doi：10.4268/cjcmm20131301
[责任编辑 曹阳阳], http://www.100md.com(王咏，陈军，林爱华，方芸)
[32] Luo L M， Huang Y， Zhao B X， et al. Anti-tumor and anti-angiogrnic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel[J]. Erials， 2013， 34(4)：1102.
Advance in studies on NGR peptide modified liposome and its
anti-tumor performance
WANG Yong1， CHEN Jun1*， LIN Ai-hua2*， FANG Yun3
(1.Pharmaceutical College of Nanjing University of Chinese Medicine， Nanjing 210046， China；
2.The Second Clinical Medicine College Affiliated to Guangzhou University of Chinese Medicine， Guangzhou 510120， China；
3.Department of Pharmacy， Gulou Hospital Affiliated to Nanjing University， Nanjing 210008， China)
[Abstract] Aspargine-glycine-arginine (NGR)-containing peptides are targeted peptides which can be integrated with CD13 receptors on tumor vascular endothelial cells. NGR peptides are connected to liposomes to obtain NGR peptide-modified liposomes. By intravenous injection of these liposomes， NGR peptides can be combined with CD13 receptors on tumor vascular endothelial cells， position liposomes in tumor tissues， and concentrate drug in liposomes in tumor， so as to enhance the antitumor effect. The article starts with NGR peptides， summarizes definition of NGR， NGR peptide-modified liposomes， strengths and weaknesses of NGR peptide-modified liposomes in antitumor and the latest study orientation of NGR peptide-modified liposomes， and looks into the future of studies on NGR peptide-modified liposomes.
[Key words] NGR peptide； NGR petide-modified liposomes； CD13 receptor； antitumor
doi：10.4268/cjcmm20131301
[责任编辑 曹阳阳], http://www.100md.com(王咏，陈军，林爱华，方芸)